Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TAS2940 |
Synonyms | |
Therapy Description |
TAS2940 is a brain-penetrant inhibitor of EGFR and ERBB2 (HER2), potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36282234). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAS2940 | TAS 2940|TAS-2940 | EGFR Inhibitor (Pan) 62 HER2 Inhibitor 42 | TAS2940 is a brain-penetrant inhibitor of EGFR and ERBB2 (HER2), potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36282234). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04982926 | Phase I | TAS2940 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Active, not recruiting | USA | FRA | 0 |